Article Sidebar

PDF
Issue: No. 30 (2022): TẠP CHÍ Y DƯỢC THỰC HÀNH 175-SỐ 30 - 6/2022
Section: SCIENTIFIC RESEARCH WORKS
DOI: 10.59354/ydth175.2022.27
Date Published: 27/06/2023
Views 0
Downloads 0
How to Cite
Công, N. T., Thượng, L. T., & Nam, V. K. (2023). THE EFFECTIVENESS OF I-131 THERAPY IN TREATMENT DIFFERENTIATED THYROID CARCINOMA WITH LUNG METASTASIS AFTER SURGERY. Journal of 175 Practical Medicine and Pharmacy, 30, 8. https://doi.org/10.59354/ydth175.2022.27

THE EFFECTIVENESS OF I-131 THERAPY IN TREATMENT DIFFERENTIATED THYROID CARCINOMA WITH LUNG METASTASIS AFTER SURGERY

Nguyễn Thành Công1, , Lê Thanh Thượng1, Võ Khắc Nam2
1 Bệnh viện Quân y 175
2  Bệnh viện Ung Bướu TP.HCM

Main Article Content

Abstract

Purpose: Assessing the effectiveness of I-131 therapy in treatment of papillary thyroid carcinoma with lung metastasis after surgery.

Materials and Method: Retrospective study 20 cases (under 45 years old) papillary thyroid carcinoma with lung metastasis were treated by I-131 after surgery in in HCM cancer hospital from 2013 to 2022 year.

Results: The rate of complete response is 10%. 90% of cases have metastatic lymph and 75% patients have been treated over total dose of 1000mCi I-131. The diffentiation of I-131 total dose between both side of neck metastatic lymph patients and other patients are not statistical signfinication. 5-year disease free survival and overall survival rate are 100%. There are not suppresion of the bone marrow

Keywords

Papillary thyroid carcinoma, disease free survival, I-131 therapy

Article Details

References

Nguyễn Mạnh Quốc, Vũ Văn Vũ và Nguyễn Chấn Hùng (2004), “Dịch tễ học và ghi nhận ung thư”, trong: Nguyễn Chấn Hùng, Ung Bướu học nội khoa, Nhà xuất bản Y học, tr.15-20.
Mai Thế Trạch (1999), “Những kiến thức cơ bản về tuyến giáp”, Trong: Mai Thế Trạch, Nguyễn Thụy Khê, Nội tiết học đại cương, Nhà xuất bản thành phố Hồ Chí Minh, tr. 189-203.
ATA (American Thyroid Association) (2016), “American Thyroid Association Management Guideline for Adult Patients with Nodules and Differentiated Thyrod cancer”, Thyroid, Volume 26, Number 1, pp. 46-52.
Doi Sa, Woodhouse NJ (2000), “Ablation of thyroid remnant and I-131 dose in differentiated thyroid cancer”, Clin Endocrinology, 52(6), pp. 756-73.
Fallahi B, Adabin K, Majidi M et al (2011), “Incidence of second primary malignancies during a longterm surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment” Clinical Nuclear Medicine, volume 36, issue 4, pp. 277-282.
Maxon H R, Smith H.R (1991), Radioiodine -131 in the diagnostic and treatmeant of metastatic well – differentiaed throid cancer, Endocrinol Metab Clin North Am 19, pp. 685-720.
Mazzaferri EL, Jhang SM (1994), “Longterm impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med 97, pp. 418 – 428.
Robbins R.J, Larson S.M et al (2003), Treatment of thyroid cancer metastases with I-131 following thyroid hormone withdrawal or recombinant human TSH, Thyroid 3 Abstract, pp. 702,
Sweeney DC, Johnston GS (1995), “Radioiodine therapy for thyroid cancer”, Endocrinol Metabol Clin North Am 24, pp. 803 – 839.